Table 5.

Assessment of side effects and VAS (pain and sleep) changes in the groups at first, second, and third month

Parameters	First month		Second month		Third month
	Amitiriptyline %	Pregabalin %	Amitiriptyline %	Pregabalin %	Amitiriptyline %	Pregabalin %
Sleep disorders	17.1	5.6	15.2	2.7	8.3	2.7
Dizziness	5.7	16.7	5.7	13.8	2.8	6.2
Dyspepsia	0	2.8	0	2.8	0	2.8
Cardiac disorders	0	0	2.8	0	2.8	0
Sleep+cardiac disorders	5.7	0	5.7	0	5.7	0
Dizziness+dyspepsia+sleep disorders	0	5.6	0	5.6	0	5.6
	p		p		p
Pregabalin VAS (pain)	0.00	0.00	0.00	0.00	0.00	0.00
Pregabalin VAS (sleep)	0.00	0.00	0.00	0.00	0.00	0.00
Amitiriptyline VAS (pain)	0.00	0.00	0.00	0.00	0.00	0.00
Amitiriptyline VAS (sleep)	0.00	0.00	0.00	0.00	0.00	0.00

VAS: Visual Analogue Scale.